Humira Biosimilars Enter the Marketplace – Update on Navitus’ Review
The market entry of biosimilars to Humira® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...
Five Forecasts and Takeaways for Plan Sponsors in 2023
As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.
Building Specialty Pharmacy Success
Sharon Faust, PharmD, Vice President of Specialty Pharmacy for Lumicera shares a few key initiatives that will continue to create an impact for...
2022 Pharmacy Benefit Predictions: What Plan Sponsors Should Watch
Navitus’ CEO, David Fields, shares his insights into the pharmacy benefits industry that will help plan sponsors achieve greater cost savings,...
In the Pipeline: Specialty Drugs to Watch in 2022
Specialty medication development has grown rapidly, encompassing up to 80% of new FDA drug approvals in recent years. Read on to learn about the most...
[Webinar] How to Better Manage Specialty Drug Spend for Chronic Conditions
Didn’t have time to attend our recent webinar on managing chronic conditions? Don’t worry – we’ve got you covered with a recap!
Seize the Opportunity to Control Your Specialty Drug Spend
Provider-administered specialty drugs covered under the medical benefit can cost far more than their average wholesale price (AWP). As a result...
Limited Distribution Drugs: What You May Not Know (rerun)
More than 75% of pharmaceutical manufacturers are choosing to limit the number of pharmacies that can dispense certain specialty medications.1 Find...
In the Pipeline: Specialty Drugs to Watch in 2021
Despite the pandemic, manufacturers are continuing to develop new drugs, especially specialty medications. Read on for the most important specialty...
Webinar: Lowering Costs & Improving Quality of Care for Chronic Populations
Recent data shows patients with chronic conditions are largely driving health care spending, yet many plans are seeing suboptimal outcomes. So, what...
